Background. Invasive pneumococcal disease (IPD) is an important cause of morbidity among individuals infected with human immunodeficiency virus (HIV). We described incidence and risk factors for IPD in HIV-infected and uninfected individuals.
Streptococcus pneumoniae is an important cause of severe bacterial disease in human immunodeficiency virus (HIV)-infected and HIV-uninfected individuals [1] [2] [3] [4] . Incidence rates of invasive pneumococcal disease (IPD) have been reported to be up to 100 times higher among HIV-infected patients compared with the background population, and recurrences are common [5] [6] [7] [8] .
The widespread use of combination antiretroviral therapy (cART) during the last decades has changed the epidemiology of IPD in HIV-infected patients. Several studies have reported a decreased incidence of IPD after the implementation of cART that is presumed to be related to immune reconstitution [7, [9] [10] [11] . We have previously shown that the risk of pneumonia in HIV-infected individuals decreased significantly after the introduction of cART [12] but that the overall incidence of pneumonia remained significantly higher than in an HIV-uninfected matched population. In the United States, the incidence of IPD in HIV-infected patients continued to be 35-fold higher than in the general population after the introduction of cART [11] . Other studies have indicated that the incidence of IPD has remained quite unchanged after the introduction of cART [1, 13, 14] .
Clinical presentation, risk factors, and outcomes after IPD differ between HIV-infected and HIV-uninfected individuals. Ethnicity, income level, injecting drug use, alcohol abuse, smoking, prior hospitalization, comorbidity, hepatitis C virus coinfection, low CD4 T-cell counts, and high HIV RNA (viral load [VL] ) have all been associated with an increased risk of IPD [1, 7, 10, 15] , whereas the use of cART and a pneumococcal conjugate vaccine (PCV) have been associated with protection [2, 10, 15, 16] . In particular, injecting drug users (IDUs) are at higher risk of recurrent bacterial infections, including pneumonia [17, 18] . Several of these factors have also been associated with higher risk of IPD in the general population [10, 19] . A large, multicenter, observational study on risk factors and outcomes after pneumococcal pneumonia in HIV-infected and HIV-uninfected patients found an increased 14-day mortality in HIV-infected patients after adjustment for age and severity of disease [4] . Another study indicated that HIV-infected patients without comorbidities have a lower mortality than HIV-uninfected patients with higher levels of comorbidity [20] .
In Denmark, the incidence of IPD has steadily increased in the general population since the late 1980s, due to an increase in the number of cases of pneumococcal bacteremia diagnosed [21] . More recently, the epidemiology of IPD has dramatically changed after the introduction of PCV in 2007 in the national childhood immunization program [22] . The total incidence of IPD has declined by approximately 20%, mainly due to a 70% reduction in IPD in children aged <2 years, but a 20% reduction in adults aged >65 years was also seen [23] . It is not known whether these changes similarly have affected HIV-infected individuals, because the incidence of IPD has not yet been assessed, nor has the effect on the risk of IPD after the widespread implementation of cART.
The aim of this study was to examine changes in the incidence of IPD in a nationwide cohort of HIV-infected individuals after the implementation of cART in Denmark, and compare these with the incidence of IPD observed in a population of matched controls. We also assessed risk factors associated with the occurrence of IPD and related mortality.
METHODS

Study Design and Setting
This was a nationwide population-based cohort study of HIV type 1-infected and -uninfected individuals in Denmark from 1 January 1995 to 31 December 2010. The estimated prevalence of HIV among adults in Denmark, a country with a population of 5.4 million, is approximately 0.09% [24] . Treatment for HIV infection is provided at only 8 specialized HIV centers. The Danish health care system provides free, tax-supported medical care for all residents, including antiretroviral treatment for HIV infection.
The study was based on the linkage of national laboratory surveillance data on IPD, the Danish HIV Cohort Study (DHCS), and the Danish Civil Registration System (CRS). The linkage between data sources was done by using the unique 10-digit identification number provided to all residents in Denmark. We identified 19 control subjects from the background population per HIV-infected individual included in DHCS. Population controls were not registered in the DHCS and then assumed to be HIV-uninfected individuals [25] , so an individual known to be HIV infected could not be a selected to be a control. Controls were matched to the corresponding HIV-infected individual on the day the patient received the HIV diagnosis according to date of birth and sex. Death was considered to be related to IPD when the date of death was registered within 30 days after the clinical sample was obtained from the patient. 
Data Sources and Definitions
National Laboratory Surveillance Data on IPD The characteristics and completeness of the national surveillance system for IPD have previously been described and centralized at the National Neisseria and Streptococcus Reference Laboratory, Statens Serum Institut [26, 27] . All isolates are routinely serotyped as previously described [28, 29] .
We included cases of IPD defined as the isolation of S. pneumoniae from a patient's cerebrospinal fluid (CSF), blood, or both. When both CSF and blood isolates were received simultaneously, the case was categorized as meningitis. Recurrences were defined as new episodes of IPD occurring at least 30 days after the first IPD episode.
In October 2007, the 7-valent PCV (PCV7) was introduced in the Danish childhood immunization program in a 2 + 1 schedule, but in April 2010, the 13-valent vaccine (PCV13) gradually started to replace PCV7 [30, 31] .
The Danish HIV Cohort Study
The cohort includes all HIV-infected individuals followed at Danish HIV treatment centers after 1 January 1995 [24, 32] . HIV-infected individuals are followed on an outpatient basis at intended intervals of 12-24 weeks. Baseline characteristics and HIV-related parameters are registered at inclusion in DHCS and updated annually. HIV-related parameters include, among others, the route of infection, information on cART, development of opportunistic infections and other AIDS-defining illnesses, and laboratory values including CD4 T-cell counts and VL. The completeness and reliability of DHCS has been estimated to be as high as 99% for patients diagnosed with HIV infection, when comparing it to other national hospital databases [25] . Only HIV-1-infected individuals aged ≥16 years and living in Denmark were included in the study.
The Danish Civil Registration System
The CRS is a national register that contains information on birth, emigration, address, and vital status of all residents in Denmark [33] . Every person in the CRS is identified by a unique 10-digit personal number, assigned at birth or immigration.
Statistical Analysis
Median and interquartile ranges (IQRs) were determined for age, duration of HIV infection, and CD4 T-cell counts. Intergroup baseline characteristics were compared using the χ 2 test for dichotomous variables and Wilcoxon 2-sample test for continuous variables. Two-tailed P values <.05 were considered statistically significant. The person-years at risk were counted from the day HIV-infected patients entered DHCS (earliest 1 January 1995, or HIV diagnosis or immigration, whichever came last) to the date of IPD, emigration, death, or 31 December 2012, whichever was first.
Incidence rates of IPD were calculated as events per 100 000 person-years of follow-up (PYFU). To investigate the effect of the introduction of cART, we studied 3 clinically relevant periods that corresponded to the use of increasingly effective antiretroviral therapy: 1995-1996 ( pre-cART), 1997-1999 (early cART), and 2000-2012 (late cART). Incidence rates were compared by estimating incidence rate ratios (IRRs) with 95% confidence intervals (CIs).
We used a Poisson regression model to assess risk factors for the occurrence of IPD, both in the total study population and for HIV-infected individuals only. Estimates are presented as relative risk (RR) with 95% CIs. To account for changes over time in age, CD4 T-cell counts, and different time period of initiation of cART, we adjusted for these variables as time-dependent covariates by the method described by Rostgaard [34] . For the total study population, the variables entered into the model were HIV infection (yes vs no), age, and time period ( pre-, early and late cART). For HIV-infected individuals, the variables entered into the model were ethnicity (caucasian vs non-caucasian), sex (female vs men), age (per year increment), smoking (current or previous vs never), HIV transmission group, (IDUs, heterosexuals, and others vs men who have sex with men [MSM]), and time period ( pre-cART, early cART, and late cART). Latest CD4 T-cell count before IPD, latest VL measurement (undetectable [<500 copies/mL] vs detectable [≥500 copies/mL]), and being on cART before IPD (cART vs none) were included in the model as a time-dependent variable.
SAS statistical software version 9.1 (SAS Institute, Cary, North Carolina) was used for analysis.
RESULTS
Baseline Characteristics
A total of 5362 HIV-infected individuals fulfilled inclusion criteria for the study and were individually matched to 101 869 controls. Of these, 137 HIV-infected patients and 136 controls experienced an episode of IPD ( Table 1) . The mean of CD4 T-cell counts/VL measurements available per patient was 30 (IQR, 13-47) and the mean time between the last measurement before the event was 4 months (IQR, 22 days-3.4 years). HIVinfected individuals were younger at the time of IPD, and had fewer episodes of meningitis. HIV-infected individuals with IPD were more often males, IDUs, and had a lower nadir CD4 T-cell count compared with HIV-infected individuals without IPD (Table 2 ). Just over half of HIV-infected patients were on cART at the time of IPD.
Incidence of IPD
The incidence in HIV-infected and uninfected individuals declined significantly between pre-cART and early/late cART periods (Table 3) . No IPD recurrences were observed among controls. In contrast, 13 of 137 HIV-infected patients had a new IPD episode (range, 1-3). Five of the recurrences were due to a PCV13 serotype, 6 of them were among IDUs, 7 patients had CD4 counts <350 cells/µL, and 5 had detectable VL.
Factors Associated With IPD
After adjusting for confounders (sex, age, and calendar period), we found that HIV-infected individuals had an overall 24-fold increased RR of IPD compared with HIV-uninfected individuals from the background population (Table 4 ). In addition to this, male sex, age, and the earliest calendar period were independently associated with an increased risk of IPD in the total population. Among HIV-infected individuals, we found that the risk of IPD was independently associated with sex, smoking, HIV exposure group, treatment, lower CD4 T-cell counts, detectable VL, and earlier calendar periods ( Table 4 ). The risk of IPD fell over time, being 22% higher in the pre-cART period compared with the years 2000-2012, although this was not the case for IDUs (Figure 1 ).
Case Fatality Rate After IPD
The crude mortality proportion in HIV-uninfected individuals was higher than among the HIV-infected individuals (14 vs 6.5%; P = .04). Controls tended to be older and had more often pneumococcal meningitis than HIV-infected patients (Table 1 ). In the adjusted analysis, age at IPD (increase per year: RR, 1.05 [95% CI, 1.02-1.09]) was the only independent 
Serotype Distribution of Pneumococcal Isolates Causing IPD
The serotype coverage of PCVs differed slightly for HIVinfected and -uninfected individuals. The overall coverage was approximately 30% for PCV7, 60% for PCV13, and 80% for 23-valent pneumococcal polysaccharide vaccine (PPSV23) (Figure 2 ). The higher serotype coverage of PCV7 in HIVinfected individuals was statistically significant (P = .02) and was due to a higher prevalence of pediatric pneumococcal serotypes in this population.
DISCUSSION
In this nationwide population-based cohort study covering an 18-year period, we found that the excess risk of IPD among HIV-infected individuals remained high compared with the risk of IPD among HIV-uninfected individuals. Although the risk of IPD declined after the introduction of cART, HIV infection was associated with a 20-fold higher risk of IPD in the latest decade. Remarkably, the risk of IPD in HIV-infected IDUs remained unchanged over time. In our cohort, the incidence of IPD was similar to that described in other studies on HIV-infected populations [2, 7, 11, 13] . In the United States, the availability of cART has significantly reduced the burden of IPD in patients with AIDS by approximately 50%, but the remaining risk of IPD was still approximately 35-fold higher than in the general population [11] . Several factors, including secular trends of pneumococcal disease; changes in blood culturing methods or clinical assessment protocols of HIV patients [13] ; and changes in hostrelated risk factors, such as an increasing proportion of HIV patients with comorbidities and IDUs [1, 13, 20] , can at least partially explain this finding. A limited effect of cART in reestablishing efficient antibody responses and preventing pneumococcal disease has also been suggested [13, 35, 36] .
HIV infection is an important risk factor for IPD in our and other study populations [5, 37] , and increasing age and male sex were also identified as factors that were independently associated with IPD [19, 38] . Among HIV-infected patients, the risk of IPD was additionally associated with injecting drug use, smoking, lower CD4 T-cell counts, and higher VL, in agreement with findings from other studies [1, 10, 15, 39] . The receipt of cART at the individual level was protective. The association of injecting drug use and smoking was not possible to address in the control population in this study.
We observed a lower mortality among patients with IPD among HIV-infected individuals compared with the HIV-uninfected population. In our study, HIV-uninfected individuals were older at the time of IPD and had a relatively higher proportion of pneumococcal meningitis (Table 1) , all known risk factors associated with mortality after IPD [8, 19] . A previous study from the United States similarly found that mortality after IPD in HIV-infected patients was approximately one-fifth of that of the HIV-uninfected patients [20] . The investigators attributed the lower mortality to a younger age and less comorbidity among HIV-infected patients with IPD. However, due to limitations in our study design, we were not able to verify the effect of comorbidity on mortality after IPD, and further studies are needed to clarify this hypothesis. Also, the number of deaths after IPD was relatively small. HIV-infected individuals in ambulatory care may have earlier access to care by specialized infectious disease physicians, and thus may have received adequate care at an earlier time point.
The effectiveness of PPSV23 vaccination on HIV-infected individuals receiving cART remains controversial, and research on the impact of conjugate vaccines on IPD in HIV-infected patients is still needed [3, 13, 35, 40] . A recent study from Malawi showed that PCV7 was effective in protecting HIV-infected individuals from recurrent IPD caused by PCV7 serotypes and 6A [16] . The introduction of general conjugate pneumococcal vaccination in young children in the United States has reduced the incidence of IPD in nonvaccinated persons, including HIVinfected individuals, through the vaccines' indirect effect [41] . HIV-infected individuals have higher rates of carriage and infections caused by the so-called pediatric pneumococcal serotypes (groups 6, 14, 19, and 23) [2, [42] [43] [44] . We found a similar pneumococcal serotype distribution in our study, thus providing preventive opportunities for using PCVs. However, we did not take into account seasonal variations and epidemiological trends of pneumococcal serotypes over the study period [21] . Studies exploring the immunogenicity of PCVs in HIV-infected individuals receiving cART are important, as pneumococcal vaccination is the only available tool for preventing pneumococcal disease. In light of our results, IDUs might be an important target group for pneumococcal immunization, because they had the highest susceptibility to the disease over time despite the availability of treatment.
The present study has certain limitations. It is possible that the greater absolute disease incidence and relative lower mortality after IPD in the HIV-infected population could be affected by referral bias, as febrile HIV-infected individuals are more likely to have taken blood cultures and in our setting are often seen in infectious disease outpatient clinics. Also, the RR estimates for HIV-infected individuals might be overestimated, as rates were obtained by comparing incidences of IPD in HIV-infected individuals vs those observed in controls, in whom the incidence of IPD is relatively low compared with the incidence in youngest children and the elderly [21] . However, it is possible that the true incidence of IPD was probably underestimated in both HIV-infected and non-HIV-infected individuals, because only cases with positive CSF or blood cultures were included in the study. However, cases of pneumococcal infection of other sterile sites (eg, pleural, synovial, or peritoneal) are not ascertained systematically in Denmark, and to maintain a high order of specificity, we included only blood and CSF specimens. We were not able to retrieve information regarding comorbidity, social factors such as crowding or alcoholism, socioeconomic status, or pneumococcal vaccination status, all of which might influence the incidence of IPD in the study population. A sensitivity analysis to address the problem of potential residual confounding such as comorbidity and the use of immunosuppressive therapy would be of great value to further validate our findings and constitute a field for future analyses.
In conclusion, the incidence of IPD in HIV-infected individuals remained significantly higher than the incidence observed in HIV-uninfected individuals, despite the widespread use of cART in Denmark. IDUs have a remarkably high risk of IPD that has not declined over time, and remain an obvious group for targeted pneumococcal vaccination. Injecting drug use, smoking, and the receipt of cART are suitable targets for preventive measures in the future.
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